Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

NCT02907099 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG: CXCR4 Antagonist BL-8040
BIOLOGICAL: Pembrolizumab
OTHER: Pharmacological Study

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]